Wednesday, 20 March 2019

Dr. Reddy's Laboratories Announces the Launch Of Trastuzumab Biosimilar In India

26 July 2018 | News

Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials.

Image Credit: Dr. Reddy's Laboratories

Image Credit: Dr. Reddy's Laboratories

Dr. Reddy’s Laboratories Ltd. has announced that it has launched Hervycta (trastuzumab), a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer).

Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials.

Commenting on the launch, MV Ramana, CEO-Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories, said, “We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space.”

Dr. Raymond De Vré, Senior Vice President and Head, Biologics, Dr. Reddy’s Laboratories, added, “The launch of Hervycta will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high quality, affordable and innovative medicines.”

Herceptin, marketed as Herclon in India and its biosimilars had India sales of approximately INR 290 Crore MAT for the most recent twelve months ending in December 2017, according to Ipsos*.

Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.

*Ipsos India Tandem Oncology Monitor 2017


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls